Driving innovation
for Life Sciences in Europe

About EUCOPE

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is Europe’s trade body that gives a bigger voice to small and mid-sized innovative companies working in the field of biopharmaceuticals and medical technologies. Through its members, EUCOPE represents 2600+ biopharmaceutical companies that are researching, designing, developing, supplying, manufacturing, and deploying the next generation of pharmaceutical innovation and therapeutic solutions around the continent.

Based in Brussels, Belgium, EUCOPE’s commitment is to lead and engage in partnerships spanning the entire medicine lifecycle to find actionable solutions that benefit our members, the patients they serve, and healthcare systems overall. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through ground-breaking therapies and medical technology. We provide a platform for discussion on major healthcare topics and developments, provide ad hoc expertise and updates on national market access and HTA issues and ensure that our members’ voices are heard first in the early stages of policy-making and legislative procedures.

Read more…

Upcoming Events

25
Feb

25. February 2026

EUCOPE Members Meeting

For further information, please contact Saskia Jansen.

17
Jun

17. June 2026

EUCOPE Members Meeting

For further information, please contact Saskia Jansen.

21
Oct

21. October 2026

EUCOPE Members Meeting

For further information, please contact Saskia Jansen.

Our Events Section

News & Updates

European Parliament adopts the Critical Medicines Act: EUCOPE warns against unintended consequences on innovation

Brussels, 20 January 2026 – The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) acknowledges today’s adoption of the Critical Medicines Act (CMA) by the European Parliament, which upholds the approach set out in the Public Health Committee (SANT) report endorsed in December 2025. EUCOPE reiterates the… read more

New study highlights contribution of €98 billion by the small to mid-sized biopharmaceutical industry as represented by EUCOPE to the EU economy and growing exposure to global policy uncertainty

Findings to be discussed in EUCOPE webinar on 4 February 2026 Brussels, January 2026 – A new study quantifying the economic footprint of the small to mid-sized biopharmaceutical industry as represented by EUCOPE shows that EUCOPE member companies make a substantial contribution to the EU27… read more

The EU Raises Its Biotech Ambition — EUCOPE Welcomes the Act’s Strategic Direction

Brussels, 17 December 2025 – The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) recognises the publication of the European Biotech Act Part I, as a promising initiative. This Act acknowledges biotechnology and biomanufacturing as strategic pillars for the EU’s competitiveness, health resilience and scientific leadership. EUCOPE… read more

EUCOPE response to the SANT report on the Critical Medicines Act

On 15 December 2025, the European Parliament Public Health Committee (SANT) adopted its report on the Critical Medicines Act (CMA). The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) deems that the adopted text marks a troubling shift away from the CMA’s original purpose: addressing shortages of… read more

EUCOPE statement on the political agreement on the EU General Pharmaceutical Legislation

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) acknowledges the provisional political agreement reached on the EU General Pharmaceutical Legislation (GPL) and recognises the efforts of the EU Institutions to modernise the pharmaceutical framework for the first time in over 20 years. This revision will have… read more

EUCOPE: Council position on the Critical Medicines Act brings improvement – but further work is needed

On 2 December 2025, EU Ministers of Health in the Employment, Social Policy, Health and Consumer Affairs Council (EPSCO) formally adopted its General Approach on the Critical Medicines Act (CMA). EUCOPE appreciates the clear distinction between measures applying to critical medicines and to medicinal products… read more

EUCOPE Publishes White Paper on Strengthening ATMP Manufacturing in Europe

EUCOPE’s Cell & Gene Therapy Working Group has published a new White Paper on ATMP Manufacturing, outlining the key barriers that innovators face in bringing advanced therapies to patients across Europe and proposing concrete solutions to strengthen Europe’s biomanufacturing landscape. The paper identifies five critical challenge areas—from… read more

SOUNDS OF SCIENCE PODCAST EPISODE #23 – Impact of EU legislations on the competitiveness of the life sciences sector

Sounds of Science – Episode 23 Competitiveness in Life Sciences: Report on Impact of EU Legislations In this episode of EUCOPE Sounds of Science, we launch the report titled Competitiveness of the EU Life Sciences Sector – Analysis of the impact of current and future EU legislations… read more

EUCOPE and Copenhagen Economics Publish New Report on the impact of EU Legislations on Life Sciences Competitiveness

Press Release Brussels, 17 November 2025 Today, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) published a new report titled Competitiveness of the EU Life Sciences Sector – Analysis of the impact of current and future EU legislations on the competitiveness of the EU life sciences… read more

EU Medical Countermeasures and Stockpiling Strategies: critical steps toward stronger health emergency preparedness

Brussels, 9 July 2025 – The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) reckons both the EU Medical Countermeasures and Stockpiling Strategies, published today, as positive steps toward improving the EU’s preparedness for future health emergencies. In an increasingly uncertain geopolitical scenario, strengthening the EU medical… read more

... or browse news by Tag

Patients Rare Disease Medicines innovation Regulatory Health Access Members Research COVID19 Events podcast ATMPs OMP Commission HTA Medical Devices EMA biotech Digital pharma EU Health IVDR European Commission competitiveness HERA Brexit MDR AdvancedDxs Life Science genomics European Parliament EHDS PharmaPackage SoHO Regulation data act Supply Safety GDPR clinical trial MEDTECH EHFG RNA clinical trials cancer

Our News Section

Interested in becoming a member?

EUCOPE gives voice to small to medium-sized innovative companies active in the field of pharmaceuticals, biotechnologies, and medical technologies at the European level. Learn more about the benefits of membership with EUCOPE.

Benefits of membership